. Author manuscript; available in PMC: 2013 Jan 1.

Published in final edited form as: Cancer Gene Ther. 2012 Apr 20;19(7):443–450. doi: 10.1038/cgt.2012.14

Table 1. Tumor inflammation in response to systemic VSV-IFN treatment.

Inflammatory infiltrate in tumors processed for H&E 15 days post IV PBS, VSV-mIFNβ or VSV-hIFNβ administration. Inflammatory infiltrate are categorized as none, minimal or slight for mixed infiltrate including fibroblasts, macrophages and lymphocytes

Treatment	Days post treatment	Inflammatory Infiltrate
PBS	15	M18	No significant inf.
VSV-mlFNβ	15	M10	Slight mixed inf.
VSV-mlFNβ	15	M45	Slight mixed inf.
VSV-hlFNβ	15	M37	No significant inf.
VSV-hlFNβ	15	M40	No significant inf.